Locations:
Search IconSearch

Preventive Cardiology

gut microbes in the human intestine

Gut Microbial TMAO Pathway Associated With Incident Heart Failure

Metabolites from animal product substrates implicated in heart failure development in community cohorts

angiogram showing microvascular disease

Bringing More Options to Bear in CAD – Part 2: Meeting Needs of Special Patient Populations

Resourceful approaches to the care of patients with microvascular disease and elevated Lp(a)

chemical structure of erythritol drawn in a teaspoon

Evidence Mounts That Sugar Substitute Erythritol Raises Cardiovascular Risk

Study authors urge reevaluation of the sweetener’s safety designation by food regulators

nutrition label of product containing xylitol

Another Sugar Substitute, Xylitol, Is Linked to Heightened Cardiovascular Risk

Studies reveal increased cardiac events, enhanced platelet reactivity and thrombotic potential

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

LDL cholesterol particle with male and female symbols atop it

CLEAR Outcomes Subanalysis Shows Bempedoic Acid’s Clinical Benefits Apply Equally to Women and Men

Reassurance from the lipid outcomes trial with the highest percentage female enrollment to date

older woman using computer

Web App Enables Safe, Effective Nonprescription Statin Use

Tech-assisted self-selection concurred with clinician-assessed eligibility in >90% of cases

photo of grains and niacin supplement pills

Link Discovered Between Excess Niacin and Cardiovascular Disease

Newly identified pathway may explain the so-called niacin paradox

19-HVI-1792159; Steven Nissen, M.D., M.A.C.C.; Mike Viars

Lipoprotein(a): Progress on One of the Last Untreatable Frontiers of Cardiovascular Risk

It's time to increase testing for this major cardiovascular risk factor in advance of new therapies

illustration showing action of a GLP-1 receptor agonist

Semaglutide Shows Secondary Cardiovascular Prevention Benefits in Patients Without Diabetes

Findings establish overweight/obesity as a modifiable risk factor for cardiovascular disease

23-HVI-4317309_lipoprotein(a)_650x450

Novel siRNA Reduces Lipoprotein(a) by More Than 90% for 48 Weeks

Undetectable levels achieved for nearly nine months in phase 1 trial

BackPage 1 of 4Next

Advertisement

Ad